A groundbreaking study presented at the Endocrine Society’s annual ENDO 2026 meeting in Chicago has unveiled a compelling connection between early-life exposure to a ubiquitous plastic chemical and the development of enduring anxiety-like behaviors in adult male rats. While the research was conducted on animal models, its implications raise significant concerns about potential long-term behavioral consequences for humans exposed to similar endocrine-disrupting compounds during critical developmental windows. The findings suggest that the foundational programming of the nervous system during prenatal and immediate postnatal periods can be profoundly influenced by environmental chemical exposures, leading to behavioral alterations that persist well into adulthood, even in the absence of continued exposure.
The chemical at the forefront of this investigation is di-(2-ethylhexyl) phthalate, commonly known as DEHP, a plasticizer extensively utilized worldwide to impart flexibility and durability to a vast array of consumer and medical products. Its presence is widespread, permeating items such as essential medical equipment, children’s toys, household furnishings like shower curtains, and outdoor apparel such as raincoats. The pervasive nature of DEHP means that exposure can occur through various routes, including ingestion, inhalation, and dermal contact, making it a significant focus of toxicological research.
Prior scientific inquiries have established that DEHP and its metabolic byproducts possess the capacity to interfere with multiple physiological systems in both animal species and humans. Notably, the reproductive and nervous systems have been identified as particularly vulnerable targets. Building upon this existing body of knowledge, researchers affiliated with the University of Buenos Aires School of Medicine embarked on a mission to meticulously examine whether early-life exposure to DEHP could instigate lasting alterations in anxiety-related behaviors in male rats. Furthermore, their investigation sought to elucidate the potential roles of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter that plays a crucial role in regulating neuronal excitability, and testosterone, a vital hormone influencing both reproductive development and neural function, in mediating these observed behavioral changes.
The experimental design involved administering daily oral doses of DEHP to pregnant female rats, commencing from the very first day of gestation and continuing without interruption until the offspring were weaned. This approach was carefully chosen to simulate potential human exposure scenarios during the critical prenatal and early postnatal developmental phases, periods characterized by rapid and sensitive neural maturation. Following the weaning process, the male offspring were monitored until they reached young adulthood, a developmental milestone defined in the study as 70 days of age.
At this designated age, the researchers employed a well-established behavioral assay, the elevated plus maze (EPM), to rigorously assess the anxiety levels of the adult male rats. The EPM is a widely recognized tool in behavioral neuroscience that capitalizes on the innate neophobic tendencies of rodents, their natural aversion to novel environments, and their inherent fear of open, elevated spaces. The maze itself is constructed in the shape of a plus sign, featuring four arms radiating from a central platform. Two of these arms are enclosed, providing a sense of security, while the other two are open, exposing the animal to the surrounding environment.
During the EPM test, researchers meticulously recorded and analyzed several key behavioral parameters. These included the frequency with which the rats ventured into each type of arm (open versus enclosed), the duration of time spent in each arm, and the extent of immobility, a behavior commonly referred to as "freezing." Freezing is often interpreted as a manifestation of fear or anxiety, indicating a reluctance to explore or move in potentially threatening situations. Rats exhibiting higher levels of anxiety are typically expected to spend less time in the exposed, open arms and more time in the sheltered, enclosed arms, while also displaying more pronounced freezing behavior.
In an effort to investigate potential therapeutic interventions and understand the underlying neurobiological mechanisms, specific subgroups of DEHP-exposed rats were subjected to further treatments. Ninety minutes prior to their evaluation in the EPM, some of these animals were administered GABA agonists. These agonists are pharmacological agents designed to mimic the action of GABA, binding to its receptors and thereby enhancing its inhibitory signaling within the brain. Concurrently, another cohort of DEHP-exposed rats received testosterone supplementation. This hormonal treatment was administered every 48 hours for a period of 14 days leading up to the behavioral testing.
The results of the behavioral assessments painted a clear and concerning picture. Male rats that had been exposed to DEHP during their early development and received no further intervention exhibited pronounced signs indicative of heightened anxiety. This was evidenced by their significantly reduced exploration of the open arms of the maze, their preference for remaining within the safety of the enclosed arms, and a marked increase in freezing behavior compared to control groups not exposed to DEHP. These findings strongly suggest that early-life DEHP exposure had a tangible and detrimental impact on their anxiety regulation.
However, the study also yielded a remarkably positive and informative outcome when considering the intervention groups. Remarkably, DEHP-exposed rats that were subsequently treated with either GABA agonists or testosterone displayed a dramatic reversal of these anxiety-related behaviors. Their behavioral patterns in the elevated plus maze shifted to resemble those of non-exposed control animals. They demonstrated increased exploration of the open arms, reduced time spent in the enclosed arms, and a decrease in freezing behavior, indicating a significant amelioration of the anxiety symptoms.
Dr. Osvaldo Juan Ponzo, a distinguished professor of physiology at the University of Buenos Aires School of Medicine and lead author of the study, elaborated on the significance of these findings. He emphasized that this research unequivocally demonstrates DEHP’s capacity to induce lasting behavioral modifications related to anxiety when exposure occurs during the formative stages of life, irrespective of whether DEHP is present in the adult environment. The observed neuroendocrine changes, he noted, are not immutable and can be effectively counteracted through targeted interventions such as the administration of GABA agonists or testosterone. This suggests that DEHP may disrupt critical developmental pathways that regulate mood and stress responses, but these pathways retain a degree of plasticity that can be influenced by specific neurochemical and hormonal signaling. The study underscores the profound sensitivity of the developing brain to environmental chemical insults and highlights the complex interplay between environmental factors, neurochemistry, and behavior. The identification of GABA and testosterone as key mediators in this process opens avenues for further research into potential preventative or therapeutic strategies for individuals potentially exposed to similar endocrine-disrupting chemicals.
About the Author
